Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Immune Pharmaceuticals (IMNP) Share Price

Press coverage about Immune Pharmaceuticals (NASDAQ:IMNP) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.0901329154729 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Separately, Maxim Group initiated coverage on shares of Immune Pharmaceuticals in a research note on Friday, January 5th. They issued a “buy” rating and a $3.00 price objective for the company.

Immune Pharmaceuticals (IMNP) traded down $0.01 during midday trading on Friday, hitting $0.59. 1,725,237 shares of the stock traded hands, compared to its average volume of 1,476,162. The company has a current ratio of 0.03, a quick ratio of 0.03 and a debt-to-equity ratio of 3.04. Immune Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $5.02. The stock has a market capitalization of $10.78, a price-to-earnings ratio of -0.14 and a beta of 2.03.

Immune Pharmaceuticals (NASDAQ:IMNP) last posted its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.34) EPS for the quarter.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Immune Pharmaceuticals (IMNP) Share Price” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-immune-pharmaceuticals-imnp-share-price/1848580.html.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

Insider Buying and Selling by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.